AU2013353542B2 - Pyrimidine-2,4-diamine derivatives for treatment of cancer - Google Patents

Pyrimidine-2,4-diamine derivatives for treatment of cancer Download PDF

Info

Publication number
AU2013353542B2
AU2013353542B2 AU2013353542A AU2013353542A AU2013353542B2 AU 2013353542 B2 AU2013353542 B2 AU 2013353542B2 AU 2013353542 A AU2013353542 A AU 2013353542A AU 2013353542 A AU2013353542 A AU 2013353542A AU 2013353542 B2 AU2013353542 B2 AU 2013353542B2
Authority
AU
Australia
Prior art keywords
amino
optionally substituted
substituents selected
dimethylphenyl
cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013353542A
Other languages
English (en)
Other versions
AU2013353542A1 (en
Inventor
Matthieu Desroses
Thomas Helleday
Sylvain JACQUES
Marie-Caroline JACQUES-CORDONNIER
Tobias Koolmeister
Martin Scobie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
Original Assignee
THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50828272&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013353542(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING filed Critical THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING
Publication of AU2013353542A1 publication Critical patent/AU2013353542A1/en
Application granted granted Critical
Publication of AU2013353542B2 publication Critical patent/AU2013353542B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013353542A 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer Active AU2013353542B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261797022P 2012-11-27 2012-11-27
US61/797,022 2012-11-27
SE1251332-1 2012-11-27
SE1251332 2012-11-27
PCT/SE2013/051387 WO2014084778A1 (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer

Publications (2)

Publication Number Publication Date
AU2013353542A1 AU2013353542A1 (en) 2015-07-02
AU2013353542B2 true AU2013353542B2 (en) 2018-04-05

Family

ID=50828272

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013353542A Active AU2013353542B2 (en) 2012-11-27 2013-11-26 Pyrimidine-2,4-diamine derivatives for treatment of cancer

Country Status (19)

Country Link
US (3) US9604937B2 (enExample)
EP (1) EP2925744B1 (enExample)
JP (1) JP6322205B2 (enExample)
KR (1) KR102194646B1 (enExample)
CN (1) CN105143206B (enExample)
AU (1) AU2013353542B2 (enExample)
BR (1) BR112015011497B1 (enExample)
CA (1) CA2888338C (enExample)
CL (1) CL2015001437A1 (enExample)
IL (1) IL238942B (enExample)
MX (1) MX373786B (enExample)
MY (1) MY182386A (enExample)
PE (1) PE20151412A1 (enExample)
PH (1) PH12015501058B1 (enExample)
PL (1) PL2925744T3 (enExample)
RU (1) RU2672916C2 (enExample)
SG (1) SG11201503783VA (enExample)
WO (1) WO2014084778A1 (enExample)
ZA (1) ZA201503470B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8729263B2 (en) 2012-08-13 2014-05-20 Novartis Ag 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions
PL2925744T3 (pl) * 2012-11-27 2021-06-14 Thomas Helledays Stiftelse För Medicinsk Forskning Pochodne pirymidyno-2,4-diaminy do leczenia nowotworu
WO2015172747A1 (en) * 2014-05-16 2015-11-19 Zhaoyin Wang Spirocyclic molecules as mth1 inhibitors
WO2015187088A1 (en) * 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of cancer
WO2015187089A1 (en) * 2014-06-04 2015-12-10 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
AU2015274285C1 (en) 2014-06-13 2021-07-01 The Brigham And Women's Hospital, Inc. Pyrimidine compounds and methods using the same
CN104292213A (zh) * 2014-09-08 2015-01-21 湖南华腾制药有限公司 一种嘧啶衍生物的制备方法
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
WO2016128140A1 (en) 2015-02-13 2016-08-18 Merck Patent Gmbh Pyrimidine derivatives for use in the treatment of cancer
WO2016135139A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135137A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135138A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016135140A1 (en) 2015-02-23 2016-09-01 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh 4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
WO2016145383A1 (en) * 2015-03-11 2016-09-15 Board Of Regents, University Of Texas System Mth1 inhibitors for treating disease
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
CN106928192B (zh) * 2015-12-29 2020-11-13 中国科学院广州生物医药与健康研究院 一种嘧啶类化合物及其制备方法和应用
CN105732516A (zh) * 2016-03-09 2016-07-06 哈尔滨医科大学 一种合成mth1蛋白抑制剂th287的方法
US10981899B2 (en) 2016-04-28 2021-04-20 Cornell University Inhibitors of soluble adenylyl cyclase
KR101876514B1 (ko) * 2016-11-08 2018-07-10 한국화학연구원 신규한 피리미딘화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암 및 염증질환의 예방 또는 치료용 약학적 조성물
JP7159214B2 (ja) 2017-05-18 2022-10-24 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのフェニル誘導体
JP7159215B2 (ja) 2017-05-18 2022-10-24 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのピリミジン誘導体
TW201900179A (zh) 2017-05-18 2019-01-01 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
CN111065635B (zh) * 2018-01-04 2022-07-22 无锡安万生物科技有限公司 作为mth1抑制剂的新型嘧啶衍生物
CN112074511B (zh) 2018-03-01 2024-04-26 托马斯·黑勒戴药物研究基金会 取代的苯并二唑及其在治疗中的用途
WO2020210521A2 (en) * 2019-04-12 2020-10-15 The Regents Of The University Of California Compositions and methods for increasing muscle mass and oxidative metabolism
EP4038065A1 (en) * 2019-09-30 2022-08-10 F. Hoffmann-La Roche AG Substituted pyrimidine for the treatment and prophylaxis of hepatitis b virus infection
KR20220101138A (ko) * 2019-11-13 2022-07-19 제넨테크, 인크. 치료적 화합물 및 사용 방법
CN110872291B (zh) * 2019-11-26 2021-06-25 五邑大学 一种四氢吡啶并嘧啶类化合物及其制备方法和应用
CN111557940A (zh) * 2020-05-28 2020-08-21 青岛大学附属医院 Mth1抑制剂th588在制备治疗多发性骨髓瘤的药物中的应用
US11787775B2 (en) 2020-07-24 2023-10-17 Genentech, Inc. Therapeutic compounds and methods of use
GB202108249D0 (en) * 2021-06-09 2021-07-21 Univ Of Sussex Compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB681712A (en) * 1949-09-14 1952-10-29 Burroughs Wellcome Co Improvements in or relating to therapeutically useful pyrimidine compounds
US2691655A (en) * 1952-05-24 1954-10-12 Burroughs Wellcome Co 2-amino-4-substituted amino-6-aryl pyrimidines and process of preparing same
EP0210228A1 (en) 1985-02-05 1987-02-04 The Upjohn Company 4-substituted-6-aryl pyrimidine compounds
US6169086B1 (en) 1997-01-27 2001-01-02 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives
CN1320122A (zh) * 1998-07-24 2001-10-31 第一制药株式会社 吡唑衍生物及其盐
WO2002096867A2 (en) 2001-05-30 2002-12-05 Lg Biomedical Institute Inhibitors of protein kinase for the treatment of disease
HRP20040098B1 (en) 2001-08-13 2012-08-31 Janssen Pharmaceutica N.V. 2,4,5-TRlSUBSTITUTED THIAZOLYL DERIVATIVES AND THEIR ANTIINFLAMMATORY ACTIVITY
US7419984B2 (en) 2002-10-17 2008-09-02 Cell Therapeutics, Inc. Pyrimidines and uses thereof
WO2004080979A1 (en) * 2003-03-14 2004-09-23 Lg Life Sciences Ltd. Novel 3-(2-amino-4-pyrimidinyl)-4-hydroxyphenyl ketone derivatives
US8084457B2 (en) 2003-09-15 2011-12-27 Lead Discovery Center Gmbh Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
EP1735319B1 (en) 2004-03-26 2017-05-03 MethylGene Inc. Inhibitors of histone deacetylase
WO2006078886A2 (en) * 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
CL2008000467A1 (es) * 2007-02-14 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de 2-aminopirimidina, moduladores del receptor histamina h4; su procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar un trastorno inflamatorio seleccionado de alegia, asma
EP2254415B1 (en) * 2008-02-19 2013-01-23 Janssen Pharmaceutica, N.V. Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
US8268846B2 (en) 2008-07-11 2012-09-18 Abbott Laboratories Amino heterocyclic linked pyrimidine derivatives
JP5743897B2 (ja) * 2008-11-20 2015-07-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ 化合物
US20120316171A1 (en) * 2009-11-05 2012-12-13 Tamas Oravecz Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer
EP2533778A1 (en) * 2010-02-10 2012-12-19 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of metastatic bone disease
CN103298460B (zh) 2010-12-14 2016-06-01 电泳有限公司 酪蛋白激酶1δ(CK1δ)抑制剂
GB201215502D0 (en) 2012-08-31 2012-10-17 Chalkiadakis Spyridon Medical use
PL2925744T3 (pl) * 2012-11-27 2021-06-14 Thomas Helledays Stiftelse För Medicinsk Forskning Pochodne pirymidyno-2,4-diaminy do leczenia nowotworu

Also Published As

Publication number Publication date
CL2015001437A1 (es) 2015-12-28
CN105143206B (zh) 2019-01-15
JP6322205B2 (ja) 2018-05-09
MX373786B (es) 2020-03-23
PL2925744T3 (pl) 2021-06-14
PH12015501058A1 (en) 2015-08-10
US9944640B2 (en) 2018-04-17
US9604937B2 (en) 2017-03-28
KR102194646B1 (ko) 2020-12-23
ZA201503470B (en) 2017-11-29
US10174029B2 (en) 2019-01-08
RU2015125458A (ru) 2017-01-11
AU2013353542A1 (en) 2015-07-02
IL238942A0 (en) 2015-07-30
MX2015006039A (es) 2015-10-20
CA2888338A1 (en) 2014-06-05
PH12015501058B1 (en) 2015-08-10
US20180170929A1 (en) 2018-06-21
MY182386A (en) 2021-01-22
RU2672916C2 (ru) 2018-11-21
EP2925744B1 (en) 2020-12-30
SG11201503783VA (en) 2015-06-29
HK1216025A1 (en) 2016-10-07
JP2016504289A (ja) 2016-02-12
EP2925744A4 (en) 2016-08-24
EP2925744A1 (en) 2015-10-07
US20170217961A1 (en) 2017-08-03
IL238942B (en) 2018-02-28
BR112015011497B1 (pt) 2023-01-10
WO2014084778A1 (en) 2014-06-05
CN105143206A (zh) 2015-12-09
PE20151412A1 (es) 2015-10-10
US20160002175A1 (en) 2016-01-07
BR112015011497A2 (pt) 2017-07-11
CA2888338C (en) 2021-07-20
KR20150087271A (ko) 2015-07-29

Similar Documents

Publication Publication Date Title
AU2013353542B2 (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer
JP6635949B2 (ja) 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤
KR102374844B1 (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
US10179790B2 (en) MTH1 inhibitors for treatment of cancer
BRPI0713328A2 (pt) derivados de piridina e pirazina como inibidores de cinase mnk
AU2008229147A1 (en) Chemical compounds
EP3083631B1 (en) Wnt pathway modulators
WO2020151589A1 (zh) 酰胺基桥连杂环类化合物、及其组合物与应用
AU2016307438B2 (en) Tricyclic compounds and their use in the treatment of cancer
HK1216025B (en) Pyrimidine-2,4-diamine derivatives for treatment of cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)